Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab

ARTAÇ, MEHMET; UYSAL, MÜKREMİN; KARAAĞAÇ, MUSTAFA; Korkmaz, Levent; Er, Zehra; Guler, Tunc; Boruban, Melih; Bozcuk, Hakan

doi:10.1007/s12029-016-9879-4

Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab

Copy For Citation

ARTAÇ M., UYSAL M., KARAAĞAÇ M., Korkmaz L., Er Z., Guler T., ...More

JOURNAL OF GASTROINTESTINAL CANCER, vol.48, no.2, pp.176-180, 2017 (ESCI)

Publication Type: Article / Article
Volume: 48 Issue: 2
Publication Date: 2017
Doi Number: 10.1007/s12029-016-9879-4
Journal Name: JOURNAL OF GASTROINTESTINAL CANCER
Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus
Page Numbers: pp.176-180
Keywords: CRP, Neutrophil/lymphocyte ratio, Metastatic colorectal cancer, Bevacizumab, Systemic inflammation, C-REACTIVE PROTEIN, LYMPHOCYTE RATIO, CHEMOTHERAPY, NEUTROPHIL, INDICATOR, CRITERIA
Akdeniz University Affiliated: Yes

Abstract

Purpose Metastatic colorectal cancer (mCRC) is a lethal disease and fluorouracil-leucovorin-irinotecan (FOLFIRI) plus bevacizumab (bev) is a standard approach. Hence, there is a strong need for identifying new prognostic factors to show the efficacy of FOLFIRI-bev.